CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 21,379 enrolled
Drug / intervention
Ticagrelor 90 mg +2 moredrug
Likely dose
Ticagrelor 90 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01225562
NCT01225562Phase 3Completed

A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multinational Trial, to Assess the Prevention of Thrombotic Events With Ticagrelor Compared to Placebo on a Background of Acetyl Salicylic Acid (ASA) Therapy in Patients With History of Myocardial Infarction

AstraZeneca·interventional·Posted Oct 21, 2010·Updated Jan 25, 2016

In Brief

A Phase 3 clinical trial evaluating Ticagrelor 90 mg, Ticagrelor 60 mg, and 1 other intervention for Myocardial Infarction and 3 related conditions. Completed, enrolled 21,379 participants across 826 sites in 31 countries.

Detailed Summary

This study is being carried out to see if a new drug called ticagrelor given twice daily in addition to the ASA therapy decreases the frequency of cardiovascular events (e.g., death from heart disease, heart attack, or stroke).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesArgentina, Australia, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Czechia, France, Germany, Hungary, Italy, Japan, Netherlands, Norway, Peru, Philippines, Poland, Romania, Russia, Slovakia, South Africa, South Korea, Spain, Sweden, Turkey (Türkiye), Ukraine, United Kingdom, United States
Collaborators--

Timeline

Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedOct 21, 2010
Enrollment StartOct 1, 2010
Primary CompletionDec 1, 2014
TodayJul 2, 2026
Enrollment to primary: 4.2 yearsPosted 15.7 years ago

Interventions

Ticagrelor 90 mgdrug

Oral dose twice a day

Ticagrelor 60 mgdrug

Oral dose twice a day

Ticagrelor Placebodrug

Oral dose twice a day